InnoCare Pharma Ltd. AI Stock Analysis
InnoCare Pharma Ltd. (INCPF) AI Stock Analysis
InnoCare Pharma Ltd.
(Other OTC:INCPF)
No summary available
InnoCare Pharma Ltd. (INCPF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $17.51B
- Dividend Yield
- ―
- Average Volume (3M)
- 1,350
- Price to Earnings (P/E)
- 12.8
- Beta (1Y)
- 0.24
- Revenue Growth
- 145.74%
- EPS Growth
- ―
- Country
- US
- Employees
- 1,388
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
InnoCare Pharma Ltd. Business Overview & Revenue Model
Company Description
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wi...
InnoCare Pharma Ltd. Earnings Call Summary
The call presents a strongly positive commercial and financial picture in H1 2026: double-digit topline growth (55.5% YoY), a return to profitability (RMB 240 million net profit), strong cash (~RMB 8.4 billion) and positive operating cash flow. R&D investment is ongoing with multiple regulatory approvals/submissions, several Phase III successes, and broad pipeline progress (notably mesutoclax and ADC programs). Key risks are timing and execution of large Phase III programs, dependence on orelabrutinib for near-term revenue, the early-stage nature of many solid tumor programs, BD deal timing uncertainty, and safety/enrollment risks in some autoimmune programs. Overall, the highlights (robust growth, profitability, cash, approvals, and positive late‑stage data) outweigh the lowlights (timing, execution and competitive risks).
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated confidence in 2026 financial and operational targets: full‑year drug sales growth above 35% (building on H1 drug sales of RMB 918m, +43.2% YoY) and strong topline momentum after H1 total revenue of RMB 1.137bn (+55.5% YoY); H1 net profit was RMB 240m (vs a RMB 36m loss a year ago) with diluted EPS of RMB 0.14 and management expects full‑year profitability with EPS above the H1 level. Liquidity and investment metrics were highlighted—cash and related accounts of ~RMB 8.4bn (~$1.2bn) as of June 30, positive operating cash flow in H1, and R&D spend of RMB 497m (up 10.5% YoY)—and the company guided to multiple near‑term clinical and regulatory catalysts (e.g., first‑line CLL/SLL Phase III fixed‑duration readout H1 2027, anticipated ITP NDA approval by H1 2027, Phase I completions for ICP‑538 and ICP‑054 by year‑end, and a US IND for ICP‑B381 expected in September) to drive continued commercial expansion.
InnoCare Pharma Ltd. Peers Comparison
Overall Rating
HK:231556Neutral
HK:685550.1Neutral
HK:968850Neutral
HK:261646.6Neutral
HK:217140Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2315 | 56Neutral | HKD 19.47B | 41.39 | 15.94% | ― | 48.04% | 166.72% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:6855 | 50Neutral | HKD 10.85B | -6.14 | -153.78% | ― | 70.26% | -12.79% |
| HK:9688 | 50Neutral | HKD 26.40B | -14.26 | -31.11% | ― | 0.28% | 8.30% |
| HK:2616 | 47Neutral | HKD 8.60B | -16.38 | -43.54% | ― | 116.67% | -0.42% |
| HK:2171 | 40Underperform | HKD 6.58B | -55.28 | -9.45% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| INCPF | InnoCare Pharma Ltd. | 1.49 | -0.64 | -30.05% | |
| HK:9688 | Zai Lab Ltd | 20.24 | 3.61 | 21.71% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.44 | -7.04 | -40.27% | |
| HK:2315 | Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H | 41.40 | 7.82 | 23.29% | |
| HK:2616 | CStone Pharmaceuticals | 5.21 | -0.54 | -9.48% | |
| HK:6855 | Ascentage Pharma Group International | 28.10 | -37.15 | -56.93% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.